WWOX SNP Genotyping for Arginine Deprivation Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict patient responsiveness to arginine deprivation therapy due to the development of resistance through reactivation of ASS1, necessitating a need for identifying genetic markers that can predict tumor response to this therapy.
Innovation Solution
The method involves determining the presence of specific SNPs in the WWOX gene, such as rs13338697 and rs6025211, using primers to amplify target nucleic acids, to predict responsiveness or non-responsiveness to arginine deprivation therapy, particularly for HCC patients, and using a kit that includes these primers for genetic analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arginine deprivation therapy is used to treat tumors, then tumor growth is inhibited initially, but resistance develops through reactivation of ASS1
Solution Approach 1:
The patent performs SNP genotyping analysis of the WWOX gene before initiating arginine deprivation therapy to identify patients who are likely to respond. This preliminary genetic screening allows clinicians to select appropriate candidates who will maintain therapeutic response without developing resistance, thereby resolving the contradiction between initial effectiveness and long-term durability.
2Measurement precision
If genetic markers are identified to predict therapy response, then treatment selection is improved, but complexity of patient assessment increases
Solution Approach 1:
The patent extracts and analyzes only the specific SNP variants within the WWOX gene that are predictive of therapy response. By focusing on these particular genetic markers rather than performing comprehensive genomic analysis, the method achieves high prediction accuracy while maintaining relatively simple and manageable assessment procedures.
Data Source
AI summary
Disclosed herein are methods and kits for identifying responsiveness or non-responsiveness of a cancer subject to arginine deprivation therapy. The method includes determining the presence of a G/G genotype of rs13338697 of the target nucleic acid in a biological sample derived from the subject by use of a polymerase chain reaction (PCR)-based method, in which the presence of the G/G genotype of rs13338697 of the target nucleic acid is an indication that the subject is responsive to the arginine deprivation therapy.